Patent Licensing Basics

Exclusive License

• The licensee is the ONLY entity (including the licensor/patent owner) that has the right to practice the patent in the licensed field
• The patent owner cannot use the patent in the licensed field during the exclusive license term
• The most valuable type of license from the licensee's perspective

Standing to Sue

• An exclusive licensee generally has standing to bring patent infringement suits, either alone or by joining the patent owner
• Waterman v. Mackenzie (S.Ct. 1891): exclusive licensee has full title to the right and can sue for infringement
• The patent owner must be joined as an indispensable party in most circuits (or consent to the suit) unless the exclusive licensee has ALL substantial rights

Non-exclusive License

• The licensor can grant the same license to multiple licensees, including the patent owner's right to practice
• Common in cross-licensing
• Technology access agreements
• Open licensing
• Generally more valuable to licensor (can maximize royalty income from many licensees)
• Licensee takes on more competitive risk (multiple licensees can compete with the same technology)
• Standing to sue: a non-exclusive licensee generally CANNOT sue for patent infringement (lacks constitutional standing — no proprietary interest in the patent)

Sole License

• A non-exclusive license where the licensor agrees not to license others (but retains its own right to practice)
• Different from exclusive: licensor can still use the technology
• Just won't license competitors

Sublicensable License

• A license that grants the licensee permission to grant sublicenses to third parties
• Important in technology transfer where the licensee will incorporate the technology into products sold through distributors or to customers who need sublicenses to use the product

Field-of-use Restricted License

• The license is limited to specific fields (pharmaceutical; consumer; government use only)
• The licensee cannot use the patent outside the defined field
• Common in university licensing and multi-market technology.

Advantages

• Aligns incentives (licensor benefits when licensee is successful)
• Lower upfront cost for licensee
• Risk-sharing

Disadvantages

• Requires audit rights and compliance monitoring
• Royalty base definition can be contested

Important

• Must specify whether the base is (a) total product price, (b) price of the component incorporating the patent, or (c) smallest unit embodying the patent
• Post-Lucent and SSPPU principles apply to avoid overvaluation

Lump Sum (Paid-up) License

• Single upfront payment for a fully paid-up license
• No ongoing royalty obligations

Advantages

• Eliminates audit risk
• Certainty for both parties
• Administrative simplicity

Disadvantages

• Licensor loses upside if licensee is more successful than anticipated
• Higher upfront cost for licensee

Hybrid

• Combination of upfront fee + running royalties
• Common structure: upfront license execution fee + running royalty percentage

Milestone-based

• Payments tied to development or commercial milestones (regulatory approval; first commercial sale; sales volume thresholds)
• Common in pharmaceutical licensing agreements

Minimum Annual Royalties

• Minimum guaranteed royalty per year regardless of actual sales
• Ensures the licensor receives minimum compensation even if the licensee underperforms or fails to commercialize
• Can trigger exclusive license reversion to non-exclusive if minimums are not met

Stepped Royalties

• Royalty rate decreases as sales volume increases (rewards high-volume commercial success)
• Or increases as sales increase (protects small licensees during ramp-up)

Most-favored-nation (MFN) Clause

• If the licensor grants a lower royalty rate to any other licensee, the MFN licensee gets the same lower rate
• Protects licensee against preferential treatment of competitors.

Problematic

• This is potentially patent misuse (the licensor extends control beyond its patent to future improvements)
• Courts scrutinize exclusive grant-backs for anticompetitive effect

Generally Acceptable

• Non-exclusive grant-backs are standard and not considered misuse
• The licensor gets access to improvements but the licensee remains free to commercialize them

Reach-through Royalties

• (in research tool licensing) royalties on downstream products developed using the licensed research tool
• Controversial
• Can be oppressive in pharmaceutical licensing

Without Explicit Grant

• The licensee cannot sublicense (Rite-Hite v. Kelley)
• The license is personal to the original licensee

Pass-through Obligations

• If sublicensing is permitted, the licensor may require that: sublicenses be in writing
• Sublicensees be bound by key license restrictions (e.g., field of use; territory; non-disparagement)
• Copies of sublicenses be provided to licensor

Audit Rights

• The licensor's contractual right to audit the licensee's records to verify royalty accuracy
• Standard provision in running royalty agreements

Audit Payment

• Shortfall + interest
• Often: licensee pays audit costs if shortfall exceeds 5-10% of reported royalties

License Term

• Typically: life of the patent (all patents in the licensed portfolio expire)
• Definite period (3-5 years with renewal options)

Important

• Royalties cannot be collected after all licensed patents expire (Brulotte v. Thys)
• Term of agreement can extend beyond patent expiration but royalty obligation must end

Exclusivity Carve-outs

• Even in an 'exclusive' license, the licensor may retain rights to: practice the patent for its own internal purposes (not commercial competition)
• Grant licenses for government use (required by 28 U.S.C. § 1498)
• Grant licenses for academic or non-commercial research
• Grant licenses to affiliates

Reversion Provisions

• Conditions under which exclusivity reverts to non-exclusive (or the license terminates): failure to meet minimum annual royalties
• Failure to achieve specific commercial milestones
• Failure to obtain regulatory approval by a specified date
• Bankruptcy of the licensee

For Cause

• Material breach (non-payment; non-reporting; breach of field restrictions)
• Licensee challenges patent validity (anti-challenge clauses; see below)
• Licensee's insolvency

Enforceability

• Courts have split on whether anti-challenge clauses are enforceable
• MedImmune v. Genentech (S.Ct. 2007): a licensee in good standing CAN bring a declaratory judgment action challenging the licensed patent
• The licensor cannot terminate the license simply because the licensee filed a DJ action

Liquidated Damages

• Some licenses specify damages for breach
• Must not be a penalty (disproportionate to anticipated harm) to be enforceable.

Royalty Base Definition

• Define 'net sales' precisely
• Specify what deductions are permitted (returns up to X%; discounts up to X%; freight; taxes)
• Vague definitions lead to disputes

Field of Use

• Define the field narrowly enough to allow licensing the patent in other fields
• A field-of-use license in 'medical devices' is much narrower than 'all uses'

Grant-back Scope

• What counts as an 'improvement'?
• Must it be based on the licensed patent?
• Does it include the licensee's own innovations that are merely combinable with the licensed technology?

Minimum Royalties and Diligence

• Ensure the licensee actually commercializes
• Minimum annual royalties create economic incentive
• Milestone provisions create legal obligation

Patent Validity Risk

• Licensing a patent does not guarantee the patent is valid
• Should include representations that the licensor knows of no prior art that would invalidate the patent
• Consider invalidity research before execution

Scope of the License

• Ensure the field of use covers the actual commercial applications
• Overly narrow field definitions can leave commercial opportunities uncovered

Right to Improvements

• Does the licensee get access to improvements made by the licensor to the licensed technology?
• Important if the patent covers a technology platform that will evolve

Patent Marking Obligations

• Does the licensor or licensee bear the obligation to mark licensed products?
• Failure to mark limits damages recovery against infringers (§ 287)

Most Common Disputes

• Royalty base calculation
• What constitutes a 'licensed product'
• Audit findings and shortfalls
• Field-of-use scope disputes
• Improvements ownership
• Sublicense royalty accounting.